108 related articles for article (PubMed ID: 710805)
21. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Hug V; Keating MJ; Chubb S
Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
[TBL] [Abstract][Full Text] [Related]
22. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.
Lauzon GJ; Paterson AR; Belch AW
Cancer Res; 1978 Jun; 38(6):1730-3. PubMed ID: 274175
[TBL] [Abstract][Full Text] [Related]
23. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
Roberts D; Peck C; Hilliard S; Wingo W
Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
[TBL] [Abstract][Full Text] [Related]
24. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
Ellens H; Rustum Y; Mayhew E; Ledesma E
J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
26. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
[TBL] [Abstract][Full Text] [Related]
27. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
28. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine.
Kataoka T; Sakurai Y
Recent Results Cancer Res; 1980; 70():147-51. PubMed ID: 7355245
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C.
Rustum YM; Riva C; Preisler HD
Semin Oncol; 1987 Jun; 14(2 Suppl 1):141-8. PubMed ID: 3589689
[No Abstract] [Full Text] [Related]
30. Mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells.
Veselý J; Pískala A
Neoplasma; 1986; 33(1):3-10. PubMed ID: 2421173
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
Cadman E; Eiferman F
J Clin Invest; 1979 Sep; 64(3):788-97. PubMed ID: 288743
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity.
Rauscher F; Cadman E
Cancer Res; 1983 Jun; 43(6):2688-93. PubMed ID: 6189585
[TBL] [Abstract][Full Text] [Related]
33. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
34. Intracellular distribution of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in blood cells.
Ueda T; Nakamura T; Kagawa D; Yamamoto K; Uchida M; Sasada M; Uchino H
Gan; 1983 Jun; 74(3):445-51. PubMed ID: 6884702
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
[TBL] [Abstract][Full Text] [Related]
36. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
Richel DJ; Colly LP; Arkesteijn GJ; Arentsen-Honders MW; Kerster MG; ter Riet PM; Willemze R
Cancer Res; 1990 Oct; 50(20):6515-9. PubMed ID: 2208110
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
38. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.
Hong F; Mayhew E
Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280
[TBL] [Abstract][Full Text] [Related]
39. Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism.
Karp JE; Donehower RC; Dole GB; Burke PJ
Cancer Res; 1984 Nov; 44(11):5046-50. PubMed ID: 6488163
[TBL] [Abstract][Full Text] [Related]
40. Lack of protein-mediated alpha-tocopherol transfer between membranes in the cytoplasm of ascites hepatomas.
Mowri H; Nojima S; Inoue K
Lipids; 1988 May; 23(5):459-64. PubMed ID: 3412126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
